The Baystreet article that BooDog posted #52509 is
Post# of 72447
(Total Views: 390)
Posted On: 01/03/2019 6:21:56 PM
The Baystreet article that BooDog posted #52509 is a MUST read. Here are some great points from the article.
===========================================================================
“There are many more similarities between these two companies that portend success and lend support to the notion that IPIX is arguably undervalued.”
“Galera and IPIX are certainly looking in the right direction in targeting head and neck cancer patients receiving chemoradiation, a treatment regimen where the incidence of SOM is stunningly high at over 70 percent. Moreover, there are no FDA-approved therapies for treating SOM in solid tumors, creating a pervasive area of high unmet medical need and a market estimated in excess of $2 billion.”
“In the case of GC4419 (Galera) for SOM, the drug is delivered intravenously.”
“oral drugs are the preferred method of administration for patients compared to laying there while the drug slowly drips through an IV. To that point, an oral drug is far more convenient, with administration available in an array of settings compared to IV. It also less expensive, likely making it the preferred method of not only insurance companies, but also doctors writing the prescriptions.”
"In the IPIX trial, treatment with Brilacidin in the modified Intent-to-Treat (mITT) population reduced the relative incidence of SOM by 65.0% compared to placebo. In the Per Protocol population, the relative incidence of SOM decreased by 80.3% compared to placebo. It bears repeating that, while the sample size was small for this group, treatment with Brilacidin oral rinse lowered the rate of SOM by over 80%."
“Innovation Pharma needs to find this quality of financial partners, but the lack of them at this point by no means justifies its paltry market capitalization of $18 million.
“For publicly-listed IPIX, whatever weight has been holding the stock down may finally be lifted so that the company can achieve a fair valuation alongside its money-raising peer so that the stock can rise from its current depressed level.”
===========================================================================
“There are many more similarities between these two companies that portend success and lend support to the notion that IPIX is arguably undervalued.”
“Galera and IPIX are certainly looking in the right direction in targeting head and neck cancer patients receiving chemoradiation, a treatment regimen where the incidence of SOM is stunningly high at over 70 percent. Moreover, there are no FDA-approved therapies for treating SOM in solid tumors, creating a pervasive area of high unmet medical need and a market estimated in excess of $2 billion.”
“In the case of GC4419 (Galera) for SOM, the drug is delivered intravenously.”
“oral drugs are the preferred method of administration for patients compared to laying there while the drug slowly drips through an IV. To that point, an oral drug is far more convenient, with administration available in an array of settings compared to IV. It also less expensive, likely making it the preferred method of not only insurance companies, but also doctors writing the prescriptions.”
"In the IPIX trial, treatment with Brilacidin in the modified Intent-to-Treat (mITT) population reduced the relative incidence of SOM by 65.0% compared to placebo. In the Per Protocol population, the relative incidence of SOM decreased by 80.3% compared to placebo. It bears repeating that, while the sample size was small for this group, treatment with Brilacidin oral rinse lowered the rate of SOM by over 80%."
“Innovation Pharma needs to find this quality of financial partners, but the lack of them at this point by no means justifies its paltry market capitalization of $18 million.
“For publicly-listed IPIX, whatever weight has been holding the stock down may finally be lifted so that the company can achieve a fair valuation alongside its money-raising peer so that the stock can rise from its current depressed level.”
(8)
(0)